ArisGlobal’s latest pharmacovigilance innovation, GenAI-powered Literature Intelligence will revolutionize literature search, intake, monitoring, and regulatory compliance

Boston, Massachusetts – September 25, 2024 – ArisGlobal, an innovative technology company at the forefront of life sciences and creator of LifeSphere®, today announced the addition of powerful GenAI functionality to Literature Intelligence.

Already streamlining literature management for leading global biopharma brands, Literature Intelligence, part of ArisGlobal’s successful LifeSphere Safety Platform, is now powered by the company’s next-generation NavaX GenAI engine. The new launch introduces Dynamic Data Extraction to enhance literature intake and assessment processes, driving increased efficiency and data accuracy.

The supercharged pharmacovigilance aid will now revolutionize the way companies approach literature search, intake, monitoring, and regulatory compliance. The newly-enhanced LifeSphere module, which can integrate readily with well-known literature and Safety databases, offers PV teams unparalleled agility and efficiency in processing the massive volumes of literature that flood the industry every month.

Key features available in Literature Intelligence include:

• Next-generation AI/ML and GenAI automation capabilities that boost the entire literature management process. With advanced AI-driven contextual analysis, data is analyzed and extracted with greater intelligence, significantly reducing errors, and improving decision-making.

• System-agnostic integration ensures seamless interoperability with companies’ existing safety systems ensures workflow optimization without disruption.

• Seamless API integration with global databases enables easy, automated literature ingestion and de-duplication from PubMed, Medline, and Embase, for comprehensive and accurate data flow into the target Safety platform.

• Automatic de-duplication and ICSR relevancy assessment which dramatically reduces timescales as manual intervention is minimized. With the ability to process large volumes of literature more efficiently, teams will stay on top of regulatory deadlines and have more time for higher-value tasks.

• Seamless integration with preferred full-text providers for automated or manual procurement. Advanced GenAI capabilities can enhance data extraction and in-depth analysis of the full-text articles too, for faster and more accurate insights.

• Tailored workflows and end-to-end automation that allows automatic ingestion to workflow segregation, de-duplication, and customizable reports, Literature Intelligence offers the flexibility to meet specific organizational needs while ensuring full compliance with global regulatory standards.

Ann-Marie Orange, ArisGlobal’s CIO and Global Head of R&D, said: “The future of biopharma literature management is here. With Literature Intelligence, global pharmaceutical companies can process vast amounts of literature more quickly, accurately, and with fewer resources. This means busy teams will be able to focus on what really matters—patient safety and regulatory compliance, leaning on cutting-edge NavaX GenAI to handle the complexities of literature intake, review, and assessment.

“This is an opportunity not just to adapt to the future of pharmacovigilance, to maintain compliance, reduce workloads, and streamline operations; it is an opportunity to lead it.”

For more information about ArisGlobal and any aspect of the LifeSphere Safety Platform, please visit www.arisglobal.com.

About ArisGlobal 

ArisGlobal, an innovative life sciences technology company and creator of LifeSphere®, is transforming the way today’s most successful life sciences companies develop breakthroughs and bring new products to market. Headquartered in the United States, ArisGlobal has regional offices in Europe, India, Japan, and China. For more updates, follow ArisGlobal on LinkedIn or visit www.arisglobal.com.